Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Thrombosis and Haemostasis

• Publication date

  2012-02-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1160/TH11-10-0718PMID 22318514
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

  2013cited by this paper
• Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

  2012cited by this paper
• Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran

  2012cited by this paper
• Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran

  2012cited by this paper
• Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.

  2012cited by this paper
• The Use of Dabigatran Immediately After Atrial Fibrillation Ablation

  2012cited by this paper
• Interpretation of point-of-care INR results in patients treated with dabigatran.

  2012cited by this paper
• Dabigatran in der Schlaganfallprävention bei Patienten mit Vorhofflimmern nach TIA oder ischämischem Insult: praktische Aspekte der Anwendung

  2011cited by this paper
• Subtherapeutic International Normalized Ratio in Warfarin-Treated Patients Increases the Risk for Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis

  2011cited by this paper
• Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.

  2011cited by this paper
• DABIGATRAN ANTICOAGULANT ACTIVITY IS NEUTRALIZED BY AN ANTIBODY SELECTIVE TO DABIGATRAN IN IN VITRO AND IN VIVO MODELS

  2011cited by this paper
• Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.

  2011cited by this paper
• Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter.

  2011cited by this paper
• Guidelines on oral anticoagulation with warfarin – fourth edition

  2011cited by this paper
• Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran

  2011cited by this paper
• Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects

  2011cited by this paper
• A propensity score-adjusted retrospective comparison of early and mid-term results of mitral valve repair versus replacement in octogenarians.

  2011cited by this paper
• Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.

  2011cited by this paper
• Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

  2011cited by this paper
• Dabigatran versus Warfarin in Patients with Atrial Fibrillation

  2011cited by this paper
• The Successful Reversal of Dabigatran-Induced Bleeding by Coagulation Factor Concentrates in a Rat Tail Bleeding Model Do Not Correlate with Ex Vivo Markers of Anticoagulation

  2011cited by this paper
• Potential Inaccuracy of Point-of-Care INR in Dabigatran-Treated Patients

  2011cited by this paper
• Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation.

  2011cited by this paper
• Dabigatran in der Schlaganfallprävention bei Patienten mit Vorho ffl immern nach TIA oder ischämischem Insult: praktische Aspekte der Anwendung Dabigatran for Stroke Prevention in Patients with TIA or Ischaemic Stroke and Atrial Fibrillation: Practical Apects

  2011cited by this paper
• Schlaganfall in der Neurologie: Eine Erfolgsgeschichte die Ihresgleichen sucht

  2011cited by this paper
• Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

  2011cited by this paper
• Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting

  2011cited by this paper
• The use of dabigatran in elderly patients.

  2011cited by this paper
• New anticoagulant drugs among elderly patients is caution necessary?: Comment on "The use of dabigatran in elderly patients".

  2011cited by this paper
• The presumed increased bleeding tendency in red‐haired individuals is not associated with von Willebrand factor antigen levels in older individuals

  2011cited by this paper
• Dabigatran Etexilate A New Oral Thrombin Inhibitor

  2011influential reference
• Newly identified events in the RE-LY trial.

  2010cited by this paper
• Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion

  2010influential reference
• New oral anticoagulant drugs in cardiovascular disease

  2010cited by this paper
• Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation

  2010cited by this paper
• Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at ‘moderate risk’ [CHADS2 score=1]: Simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice

  2010cited by this paper
• Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays

  2010cited by this paper
• Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?

  2010cited by this paper
• In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves.

  2010cited by this paper
• Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1

  2010cited by this paper
• Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

  2010influential reference
• Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran

  2010cited by this paper
• Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.

  2010cited by this paper
• Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

  2010cited by this paper
• Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

  2010cited by this paper
• Dabigatran etexilate in people with atrial fibrillation

  2010cited by this paper
• Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

  2010cited by this paper
• Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate

  2010cited by this paper
• A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

  2010cited by this paper
• Dabigatran for Atrial Fibrillation

  2009cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009influential reference
• Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

  2009cited by this paper
• Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting

  2009cited by this paper
• Consensus document on antithrombotic therapy in the setting of electrophysiological procedures.

  2008cited by this paper
• Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range

  2008cited by this paper
• Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?

  2008cited by this paper
• ON IN VITRO INVESTIGATION OF MITOCHONDRIAL TOXICITY OF ANTI-HIV NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

  2008cited by this paper
• Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature.

  2008cited by this paper
• The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans

  2008cited by this paper
• Guidelines for the Early Management of Adults With Ischemic Stroke

  2007cited by this paper
• Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

  2007cited by this paper
• Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

  2007cited by this paper
• Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.

  2007cited by this paper
• Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

  2006cited by this paper
• Effect of study setting on anticoagulation control: a systematic review and metaregression.

  2006cited by this paper
• Schattauer

  2006cited by this paper
• Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population

  2005cited by this paper
• Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation

  2005cited by this paper
• Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care

  2005cited by this paper
• Additional monitoring tools to improve the quality of anticoagulation management.

  2000cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Global Synthesis of Randomized Evidence through Network Meta-Analysis

  2025cites this paper
• Thromboembolien – Eine häufige Ursache des Schlaganfalls

  2023cites this paper
• [Thromboembolism - A common cause of stroke].

  2023cites this paper
• The impact of anticoagulation therapy on kidney function in patients with atrial fibrillation and chronic kidney disease

  2023cites this paper
• Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits

  2022cites this paper
• Development and Validation of UPLC-MS/MS Method for Quantifying of Free and Total Dabigatran in Human Plasma: An Application for a Bioequivalence Study.

  2022cites this paper
• 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.

  2021cites this paper
• Solubility measurement, correlation and molecular simulation of dabigatran etexilate mesylate polymorphs in five mono-solvents

  2020cites this paper
• Tailoring anticoagulant treatment of patients with atrial fibrillation using a novel bleeding risk score

  2020cites this paper
• Assessment of dabigatran plasma concentrations may improve the safety of anticoagulation in patients with atrial fibrillation undergoing ibrutinib treatment.

  2020cites this paper
• Newer Oral Anticoagulant Therapy – Prospects and Practices: A Review

  2020cites this paper
• Assessment of dabigatran plasma concentration may improve the safety of anticoagulation in patients treated with ibrutinib with concomitant atrial fibrillation

  2020cites this paper
• Non–Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence

  2020cites this paper
• a repository of Oral anticoagulants for prevention of stroke in atrial fibrillation : systematic review, network meta-analysis, and analysis

  2019cites this paper
• Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis

  2019cites this paper
• DABIGATRAN AND IDARUZIZUMAB. NEW OPPORTUNITIES FOR IMPROVING PATIENT SAFETY

  2019cites this paper
• Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries?

  2019cites this paper
• Atrial fibrillation in patients with end‐stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation

  2019cites this paper
• The 2018 Korean Heart Rhythm Society Practical Guidelines on the use of Non-Vitamin K-Antagonist Oral Anticoagulants: Bleeding Control and Perioperative Management

  2019cites this paper
• a repository of Oral anticoagulants for prevention of stroke in atrial fibrillation : systematic review, network meta-analysis, and analysis

  2019cites this paper
• ДАБИГАТРАН И ИДАРУЦИЗУМАБ. НОВЫЕ ВОЗМОЖНОСТИ ОБЕСПЕЧЕНИЯ БЕЗОПАСНОСТИ ПАЦИЕНТОВ

  2019cites this paper
• Novel Oral Anticoagulants and Their Role in Clinical Practice

  2019cites this paper
• Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing

  2018cites this paper
• Association between activated partial thromboplastin time, age and bleeding events in NVAF patients receiving dabigatran

  2018cites this paper
• [Medication adherence to non-vitamin K antagonist oral anticoagulants at non-valvular atrial fibrillation - the literature review].

  2018cites this paper
• HPLC-MS/MS Method for Determining Dabigatran in Human Blood Serum

  2018cites this paper
• The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

  2018cites this paper
• Safety of Recanalization Therapy in Patients with Acute Ischemic Stroke Under Anticoagulation: A Systematic Review and Meta-Analysis.

  2018cites this paper
• A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents

  2018cites this paper
• The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations

  2018cites this paper
• Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis

  2017cites this paper
• Improved oral bioavailability and therapeutic efficacy of dabigatran etexilate via Soluplus-TPGS binary mixed micelles system

  2017cites this paper
• Eingriffe unter NOAK

  2017cites this paper
• Real life dabigatran and metabolite concentrations, focused on inter-patient variability and assay differences in patients with atrial fibrillation

  2017cites this paper
• Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis

  2017cites this paper
• The prothrombotic state in atrial fibrillation : observations on fibrin clot structure and the relationship to renal dysfunction

  2017cites this paper
• Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran

  2017cites this paper
• Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report

  2017cites this paper
• Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword

  2017cites this paper
• Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal.

  2016cites this paper
• QbD Approach Method Development for Estimation of Dabigatran Etexilate along with Its Impurities and Identification of Degradants in Capsule Dosage Form

  2016cites this paper
• Editors’ Choice 2015 papers in Thrombosis and Haemostasis

  2016cites this paper
• Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting

  2016cites this paper
• Burden of upper gastrointestinal symptoms in patients prescribed dabigatran for stroke prevention

  2016cites this paper
• Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease.

  2016cites this paper
• Efficacy and safety of novel anticoagulants in the elderly

  2016cites this paper
• Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.

  2016cites this paper
• Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement.

  2016cites this paper
• Non-Vitamin K Oral Anticoagulants (NOACs) A Review of Clinical Management and Laboratory Issues.

  2016cites this paper
• Measurement and prediction of dabigatran etexilate mesylate Form II solubility in mono-solvents and mixed solvents

  2016cites this paper
• Popular naturally occurring antioxidants as potential anticoagulant drugs.

  2016cites this paper
• Title Burden of upper gastrointestinal symptoms in patientsprescribed Dabigatran for stroke prevention

  2016cites this paper
• Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation.

  2016cites this paper
• Pharmacological Measures for the Treatment and Prevention of Stroke: The Choice of Initial Therapy

  2016cites this paper
• Eteksylan dabigatranu a idarucizumab — przełomowe rozwiązanie problemów klinicznych związanych z przeciwkrzepliwym działaniem leku

  2016cites this paper
• International normalised ratio stability in patients aged 80 years and over taking warfarin for non-valvular atrial fibrillation

  2016cites this paper
• Enhanced elimination of dabigatran: Identifying the appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysis—A simulation analysis

  2016cites this paper
• Améliorer la sécurité de la prescription de dabigatran en soins courants : quel est l'intérêt du dosage du médicament ?

  2016cites this paper
• How to effectively manage the event of bleeding complications when using anticoagulants

  2016cites this paper
• Safety and Efficacy of Underdosing Non-vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Catheter Ablation for Atrial Fibrillation

  2016cites this paper
• Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease.

  2016cites this paper
• Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.

  2016cites this paper
• Design, synthesis, anticoagulant activity evaluation and molecular docking studies of a class of N-ethyl dabigatran derivatives.

  2016cites this paper
• New oral anticoagulants – a practical guide

  2015influential citation
• Analysis of the influence of dabigatran on coagulation factors and inhibitors

  2015cites this paper
• Assessing nonvitamin K antagonist oral anticoagulants (NOACs) in the laboratory

  2015cites this paper
• Clinical utility of dabigatran in United Arab Emirates

  2015cites this paper
• Rationale and Design of Triple AXEL: Trial for Early Anticoagulation in Acute Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation

  2015cites this paper
• Which Patients May Benefit from Dose Adjustment of Non-Vitamin K Antagonist Oral Anticoagulants?

  2015cites this paper
• Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic.

  2015cites this paper
• Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.

  2015cites this paper
• CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.

  2015influential citation
• Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis.

  2015cites this paper
• Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non‐valvular atrial fibrillation

  2015cites this paper
• Dabigatran treatment simulation in patients undergoing maintenance haemodialysis

  2015cites this paper
• Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal.

  2015cites this paper
• Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study

  2015cites this paper
• Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study.

  2015cites this paper
• Coagulation Testing For New Oral Anticoagulants.

  2015cites this paper
• Anticoagulants oraux, réutilisation de données hospitalières informatisées dans une démarche de soutien à la qualité des soins

  2015cites this paper
• Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients

  2015cites this paper
• The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials.

  2015cites this paper
• Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis

  2015cites this paper
• A pharmacovigilance study

  2015cites this paper
• Target-specific oral anticoagulants and the hospitalist

  2015cites this paper
• European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

  2015cites this paper
• Medikamentöse Sekundärprävention des ischämischen Schlaganfalls – Empfehlungen für den klinischen Alltag

  2015cites this paper
• How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation

  2015cites this paper
• Dabigatran in ‘real-world’ clinical practice for stroke prevention in patients with non-valvular atrial fibrillation

  2015cites this paper
• New oral anticoagulants: their role in stroke prevention in high-risk patients with atrial fibrillation.

  2015cites this paper
• Nuevos anticoagulantes orales en odontología: Dabigatran

  2015cites this paper
• Effective Reversal of Edoxaban-associated Bleeding with Four-factor Prothrombin Complex Concentrate in a Rabbit Model of Acute Hemorrhage

  2015cites this paper
• Practical issues in the management of novel oral anticoagulants-cardioversion and ablation.

  2015cites this paper
• Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.

  2015cites this paper
• Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation

  2015cites this paper
• 2014 Indonesian Heart Association Guidelines of Management of Atrial Fibrillation

  2015cites this paper
• Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C

  2014influential citation
• Dabigatran in Secondary Stroke Prevention: Clinical Experience with 106 Patients

  2014cites this paper
• Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting

  2014cites this paper
• Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants

  2014influential citation